Search This Blog

Wednesday, August 1, 2018

China’s Ascletis Debuted: Stocks Flat


Chinese biotech company Ascletis Pharma debuted on the Hong Kong stock exchange, rising as much as 6.4 percent, but ending the day where it started. Shares began trading at $14 (HK) and rose as high as $14.90 (HK) in early trading before returning by end of the trading day to $14. The listing was made under a new set of rules.
According to Reuters UK, “The rules, introduced in late April, are part of efforts to better compete with New York for listings. Currently, Nasdaq is the biggest center for biotech initial public offerings (IPOs), with $2.4 billion worth of such shares sold last year.”
Ascletis, based in Hangzhou, China, was founded in 2013 and has two drug candidates for the treatment of hepatitis C and one for HIV, which has finished a Phase IIa clinical trial. The company also has a liver cancer drug candidate, which has completed Phase I and Phase I extension clinical trials.
The new rules allow Chinese biotech companies to launch IPOs when they have not made a profit or brought in revenue yet—a condition that applies to most biotech companies, unlike typical tech companies. In biotech, an IPO is often launched to raise money to advance a product into clinical trials, particularly the more expensive Phase II and Phase III clinical trials.
After the new rules were put in place, more than 10 biotech companies, mostly Chinese, announced plans to list in Hong Kong. Some have also dropped plans to launch IPOs in the U.S. in favor of the Hong Kong exchange. Two companies that are planning to list in Hong Kong are Innovent Biologics and Shanghai Henlius Biotech.
Under the previous guidelines, the Hong Kong exchange’s biggest biotech IPOs were 3SBio,which raised $818 million in 2015 and WuXi Biologics Cayman, which raised $587 million in 2017.
There is currently an ongoing scandal in China over a biopharma company, Changsheng Bio-Technology, which is under investigation by Chinese regulators for allegedly falsifying data for several products. Shenzhen Stock Exchange has barred the company’s major shareholders and executives from selling stock and threatened to delist the company.
In November 2017, two batches of DPT vaccines made by Changsheng and the Wuhan Institute of Biological Products didn’t meet national standards. A July 2018 inspection found evidence of forged data related to the company’s manufacturing of about 113,000 rabies vaccines. At that time the State Drug Administration revoked the company’s license to produce the vaccine and initiated recalls. Vaccine production was suspended the next day and on July 17, the Jilin Food and Drug Administration fined the company 3.4 million yuan ($502,000 U.S.) over the DPT vaccines from the previous year.
Wu Jinzi, founder of Ascletis, was asked about the Changsheng scandal and said that quality was “the lifeline” of Ascletis. “We are going to make the best quality, most effective and the safest drugs for patients in China and the world,” he told Reuters.
In a country known for executing white collar criminals, that seems like a reasonable answer.

DexCom raises FY18 revenue view to about $925M from $850M-$860M


Consensus $862.25M

DaVita reports Q2 adjusted EPS $1.05, consensus 97c


Reports Q2 revenue $2.89B, consensus $2.88B.

PRA Health raises FY18 adj. EPS view to $4.13-$4.32 from $4.00-$4.15


Consensus $4.12. Sees FY18 revenue $2.87B-$2.92B, consensus $2.92B.

Express Scripts updates expected 2019 retention rate for the 2018 selling season

The Company is updating its expected 2019 retention rate for the 2018 selling season from a range of 96% to 98% to a range of 97.5% to 98.5%. “As clients benefit from better health outcomes and savings, they choose to remain our clients and adopt a greater number of Express Scripts’ product and service solutions. Put simply, we are having a strong selling season across both commercial and health plans and we now expect to grow core business adjusted claims by 2% to 3% in 2019,” said Wentworth. “Furthermore, client adoption of our new solutions, a key indicator of the relevance of our ongoing innovation, is meaningfully outperforming our expectations, with continued interest in, among others, our 90-day programs, Accredo specialty pharmacy, SafeGuardRx, Advanced Opioid Management and Advanced Utilization Management solutions.”

Herbalife Nutrition cuts FY18 adj. EPS view to $2.60-$2.80 from $5.05-$5.45


Consensus $2.73.

Intersect ENT price target lowered to $40 from $45 at Piper Jaffray


Piper Jaffray analyst Matt O’Brien lowered his price target for Intersect ENT to $40 from $45 after the company missed Q2 revenues and reduced full year 2018 guidance. Essentially, the disappointment in the quarter and for the outlook this year is the company’s key new SINUVA product, which is ramping slower than expected due to reimbursement processing issues, he notes. Although this is disappointing and there is no guarantee that more road bumps in the launch will not pop up, the analyst still believes utilization will be quite strong and growth in 2019 and beyond will be among the best in small cap med tech. O’Brien reiterates an Overweight rating on the shares.